PMC:6986229 / 7262-7543 JSONTXT

Annnotations TAB JSON ListView MergeView

    LitCovid-PubTator

    {"project":"LitCovid-PubTator","denotations":[{"id":"120","span":{"begin":147,"end":161},"obj":"Disease"},{"id":"121","span":{"begin":212,"end":225},"obj":"Disease"}],"attributes":[{"id":"A120","pred":"tao:has_database_id","subj":"120","obj":"MESH:D001943"},{"id":"A121","pred":"tao:has_database_id","subj":"121","obj":"MESH:D001943"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Trastuzumab – a monoclonal antibody – was included in the WHO Model list of essential medicines in 2015 as an essential treatment for about 20% of breast cancers. It has shown high efficacy in curing early stage breast cancer and, in some cases, more advanced forms of the disease."}

    LitCovid-sentences

    {"project":"LitCovid-sentences","denotations":[{"id":"T61","span":{"begin":0,"end":162},"obj":"Sentence"},{"id":"T62","span":{"begin":163,"end":281},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Trastuzumab – a monoclonal antibody – was included in the WHO Model list of essential medicines in 2015 as an essential treatment for about 20% of breast cancers. It has shown high efficacy in curing early stage breast cancer and, in some cases, more advanced forms of the disease."}

    LitCovid-PD-HP

    {"project":"LitCovid-PD-HP","denotations":[{"id":"T18","span":{"begin":147,"end":161},"obj":"Phenotype"},{"id":"T19","span":{"begin":212,"end":225},"obj":"Phenotype"}],"attributes":[{"id":"A18","pred":"hp_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/HP_0003002"},{"id":"A19","pred":"hp_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/HP_0003002"}],"text":"Trastuzumab – a monoclonal antibody – was included in the WHO Model list of essential medicines in 2015 as an essential treatment for about 20% of breast cancers. It has shown high efficacy in curing early stage breast cancer and, in some cases, more advanced forms of the disease."}